VIVES is a multi-sector fund that invests in projects with a positive societal impact
Promethera Biosciences’ mission is to bring patients life-saving treatments to reduce the need for liver transplantation. The company is pioneering the development of cell-based therapies that provide...
Specialized studies carried out in 2016 and 2018 show that around 2 billion people worldwide suffer from sleep dysfunctions. Of these, 1 billion suffer from obstructive sleep apnea (OSA).
These sleep...
The Akkermansia company is the first co-spin-off resulting from joint research conducted at two European universities, the Catholic University of Louvain (Belgium) and the University of Wageningen...
Denis Périquet, CEO Tessares :
"VIVES supports real innovation projects, while understanding that those projects need time to grow from the academic research phase to a commercial success. Team...
Pierre Drion, business angel :
"For almost 20 years I have been passionate about what is called biotech. This led me to invest in several companies and mainly university spin-offs. In this context, I...
Georges Caron, past CEO Keemotion :
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with...
VIVES Partners’ portfolio investment The Akkermansia Company (TAC) acquired by Danone
Acquisition of TAC’s gut microbiota product, with benefits for people at risk of cardiovascular disease
At 12 months, 100% of participants with distal radius fractures treated in trial with NVDX3, an allogenic stem-cell derived bone graft material, demonstrated durable bone union
No adverse events
BiocSol succeeds in its ambition to raise a total of €10M since inception to fast-track the development of its sustainable crop protection solutions - testament to the sector’s growing interest in its